




The Florida Cancer Data System's Memo

October 2023



The Florida Cancer Plan – FCDS Leads Work Groups to Advance Collection of Cancer Data

In the last year and a half, the FCDS has led and engaged with Florida stakeholders to advance goals and objectives in the 2020-2025 Florida Cancer Plan (<https://www.ccrab.org/cancer-plan-2020-2025>). Specifically, under goal 2, to ensure collection of comprehensive and high-quality cancer-related data from all Florida cancer patients, and to inform cancer prevention and control programs. Under this goal, four objectives were identified for which separate working groups were established. These working groups cover the following: cancer biology, data access and utilization, collection of cancer screening data, and social determinants of health. Chaired and lead by FCDS leadership, Dr. David Lee, Gary Levin, and Dr. Monique Hernandez, the workgroups engaged many stakeholders and members from across the state to include NCI designated cancer centers, community oncology practices, universities, Florida Department of Health, and members from the Florida Cancer Control and Research Advisory Council (C-CRAB). Through monthly meetings, each work group devised work plans and pilots to address the growing need for genetic data, cancer screening information, enhanced social and economic indicators to link with cancer records, and increased support of cancer data requests to the central cancer registry.

While the work groups provided an excellent road map toward achieving the goals and objectives of the Florida Cancer Plan, these activities require appropriate funding to pursue the pilots. These pilots would serve to evaluate the feasibility of ongoing and large-scale implementation for future consideration. A recent success has been under the cancer screening work group, where a two-year pilot project to collect lung cancer screening data was funded through the Tobacco Free Florida Program. This work involves adopting the standards set forth by the America College of Radiology (ACR), Lung Cancer Screening Registry (LCSR). The LCSR is a national database of lung cancer screening data. Providers voluntarily contribute their data to generate national-level benchmarks against which facilities can compare.

WHAT'S NEW:

The following information is currently available on the FCDS website.

**WEIGHT-RELATED
CANCERS IN FLORIDA
1992-2013 MONOGRAPHS**

**FCDS RESEARCH
JOURNAL PUBLICATIONS
REPORT**

**FCDS/NAACCR
EDITs Metafile
V23b Metafile,
posted on 8/18/2023**



**Florida Statewide Cancer
Registry**

(Continued on page 2)




Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 1)

These data are linkable, meaning they contain patient-level identifiers that can then be matched to records in the Florida central cancer registry database. The pilot would engage a handful of reporting facilities that already report to the LCSR, to submit the same data to the FCDS. This would serve to establish a linked lung cancer screening and lung cancer incidence database whereby researchers could evaluate important questions. Enhancing lung cancer incidence records with lung cancer screening information would help to uncover important epidemiologic questions around screening uptake, effectiveness, and impact on cancer outcomes.

We are continuing our efforts to fund all the pilots and have made some headway on identifying potential resources to keep the work going. Certainly, the support of a collaborative, team-led, and stakeholder approach, has infused great momentum into these objectives and all the work will inform the development of the forthcoming Florida Cancer Plan, which starts next year.

If you would like to know more information about these objectives, or are interested in joining any of the work groups, please contact Dr. Monique Hernandez at mhernandez5@med.miami.edu.



2023 Cancer Reporting Requirements

The NAACCR VERSION 23 standards will affect data collection in Florida starting with cases diagnosed in 2023 forward. Please be sure to read the 2023 FCDS DAM to familiarize yourself with the new requirements. Be sure you have all the necessary updated manuals on your desktop when abstracting a case.

New Data Items for FCDS:

1. Data Item # 1291- RX Summ- Surg Prim Site 2023
 - Codes starting with A indicate no significant change to the surgery code.
 - Codes starting with B indicates changes to the surgery code(s).
 - FCDS has incorporated these new surgery codes in the 2023 DAM, Appendix F.
2. Data Item # 3960- Histologic Subtype
 - This data item is only for the Appendix Schema 09190.

(Continued on page 3)



Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 2)

Revised Data Item for FCDS:

1. Data Item # 1290- RX Summ-Surg Prim Site is now RX Summ--Surg Prim Site 03-2022.
 - Only the name changed. This data item will still collect the surgery codes for cases with a diagnosis date of on or before 2022.
2. Data Item # 3956- p16
 - This is an existing SSDI for the cervix V9 (schema id 09520).
 - It is being added to the Anus V9 (schema id 09210).

Data Items No Longer Required for FCDS:

1. Date flag data items retired in 2023.
 - They will no longer be transmitted in the NAACCR record.
 - All edit checks with date flags have either been deleted or modified.

Coding Clarifications

Starting in 2023 Cases diagnosed with pilocytic astrocytoma/juvenile pilocytic astrocytoma 9421 are to be reported with behavior /1. Cases diagnosed prior to 1/1/2023 are coded 9421/3.

Starting with 2023 cases, Code 9421/3 will be valid for diagnoses of high-grade astrocytoma with piloid features (HFAP).

The following histologies have been approved for use with primaries of the cervix C53 for diagnosis year 2021 and forward. Previously, registrars were instructed to use these histologies for cervical primaries starting with cases diagnosed in 2022 forward.

- 8085 Squamous cell carcinoma, HPV-associated C51.9; C52.9; C53.X_
- 8086 Squamous cell carcinoma, HPV-independent C51.9; C52.9; C53.X_
- 8483 Adenocarcinoma, HPV-associated
- 8484 Adenocarcinoma, HPV-independent, NOS
- 8482 Adenocarcinoma, HPV-independent, gastric type
- 8310 Adenocarcinoma, HPV-independent, clear cell type
- 9110 Adenocarcinoma, HPV-independent, mesonephric type C53.X; C56.9

(Continued on page 4)



Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 3)

Solid Tumor Rules- 2023 Site Specific Updates

CNS- Malignant and Non-Malignant

New instructions were added for Pilocytic Astrocytoma tumors

Breast

Clarifications to Rule M10 and the applicable histology rules for coding lobular and ductal tumors were added; “Assign behavior code /3 even when an in-situ histology is mixed with an invasive. This aligns with ICD-O-3.2 and was vetted with specialty matter experts.”

Prostate

New Rule M4- Abstract multiple primaries when the patient has a subsequent small cell carcinoma 8041 of the prostate more than 1 year following a diagnosis of acinar adenocarcinoma and/or subtype/variant of acinar adenocarcinoma of prostate (Table 3).

Head & Neck

Table 9 was redesigned; New timing rule: Abstract multiple primaries when the patient has a subsequent tumor after being clinically disease-free for greater than five years after the original diagnosis or last recurrence.

C754 and C755 added to the H&N module.

Other Sites

This chapter was completely revised. Same format, histology coding requirements and timing instructions as the current solid tumor rules for the site-specific modules.

New Rule M8- Abstract multiple primaries when separate/non-contiguous tumors are anaplastic carcinoma and any other histologies in the thyroid. Note: This rule does not apply to multiple tumors that are anaplastic carcinoma and undifferentiated carcinoma.



Florida Cancer Data System Deadlines, Updates, & Reminders

THE FCDS RT FOLLOW BACK AUDIT FOR THE 2022 CASES IS AVAILABLE FOR REVIEW IN THE FCDS IDEA THE DEADLINE IS DECEMBER 31, 2023

FCDS completed the matching of the 2022 cancer cases identified by Radiation Treatment facilities in Florida with the FCDS database. If you are a Radiation Treatment facility, please visit the FCDS IDEA to review RT Follow Back records under the Radiation Therapy/ Follow Back menu. Please note that facilities that failed to report the 2018-2020 missed reportable cases found through the 2018-2020 Follow Back audit process are also included. These cases are considered late and must be reported immediately to FCDS to have the facility's non-compliant status updated.

The deadline for the Radiation Therapy Treatment facilities to report the 2022 cancer cases identified through the Follow Back audit process to FCDS is December 31, 2023.

The RT Follow Back process is an audit that is dictated and closely monitored by the Florida Department of Health (DOH). Facilities that fail to meet state-mandated cancer incidence data reporting requirement to the FCDS by the deadline are referred to the Florida Department of Health (DOH) for non-compliance.

Thank you for your attention to this important audit. If you have any questions, please contact your FCDS Field Coordinator, Angel (Sam) Saskia at sangel@med.miami.edu, 305-243-2638.

BI-RADS, PI-RADS, LI-RADS, and Lung RADS

What is the diagnosis date for cases using RADS? Are these imaging studies enough for us to call it cancer?

FCDS Rule:

For breast cases designated BIRADS 4, 4A, 4B, 4C or BIRADS 5 alone without any additional information are not reportable; there must be a biopsy to confirm malignancy. If positive biopsy, the date of diagnosis is the date of the imaging.

For prostate and liver cases with PI RADS and LI RADS with scores 4 and/or 5 alone without any information to the contrary, are reportable with a physician's statement. No biopsy needed. The date of diagnosis is the date of the imaging.

For lung cases, RADS alone are not to be used to determine reportability. There must be a physician statement with reportable terminology. The date of diagnosis is the date of the imaging.



Announcing NCRA's Updated Credential: ODS

Introducing ODS, Oncology Data Specialist

The National Cancer Registrars Association (NCRA) and its Council on Certification have updated the credential name of CTR, Certified Tumor Registrar, to ODS, Oncology Data Specialist. The new name better aligns with the evolving scope of practice of cancer registrars and current professional practice terminology. The use of the new credential begins January 1, 2024; NCRA anticipates the adoption will take at least a full calendar year.

CTR credential holders are encouraged to wait until January 1, 2024, to use the new credential.

Please read the **press release** and **FAQs** and view NCRA President Maria Teresa 'MT' Ramirez's recorded message to better understand the history and process behind the name change. Updates and any needed clarifications will be posted to www.ncra-usa.org/ODS at the 'Learn More' button below so please bookmark and visit frequently.

[ODS FAQs](#)

[Learn More](#)

Every 25th Quality Control Visual Review Process

The Quality Control Visual Review process is designed to facilitate visual editing of abstracted data. Facilities must review the identified coding errors in the abstract(s) and return the requested additional information to FCDS within three weeks of receipt.

Effective September 1, 2023, FCDS will begin sending facility registrars and administrators email reminders regarding this important Quality Control process. The email reminder will note the total number of abstracts that are currently in the review process, the receipt month, and the number of days overdue.

This is a sample of the data that will be included in the email.

QC Records to Review - dated before 07/31/2023		
Period	To Review	Over Due
2023-03	6	64
2023-04	1	47
2023-05	3	0
2023-06	2	0

Please keep in mind that all process conducted by FCDS are dictated and monitored by the Florida Department of Health.

We ask that facilities return the Quality Control abstracts in a timely manner.

**FCDS 2022-2023 Calendar of Reporting Calendar and
FCDS Recurring Deadlines *Dates Subject To Change***

Patient Encounter for Cancer	Case Should Be Reported
ALL 2021 CASES WERE DUE 6/30/2022	ALL 2022 CASES WERE DUE 6/30/2023
January 2023	July 2023
February 2023	August 2023
March 2023	September 2023
April 2023	October 2023
May 2023	November 2023
June 2023	December 2023
July 2023	January 2024
August 2023	February 2024
September 2023	March 2024
October 2023	April 2024
November 2023	May 2024
December 2023	June 2024
ALL 2022 CASES ARE DUE 6/30/2023	ALL 2023 CASES ARE DUE 6/30/2024

RECURRING DEADLINES		
Monthly	FC Review/Inquiry	Cases with FC Review Inquiry or correction(s) must be reviewed and responded to monthly
Monthly	QC Review/Inquiry	Cases with QC Review Inquiry or correction(s) must be reviewed and responded to monthly
June 30	Annual Reporting Deadline	All cases from previous calendar year must be reported to FCDS on or before June 30 th each year
September 1	Consolidated Follow-Back Deadline	All unmatched cases from the combined AHCA and Vital Records Death Match must be resolved by September 1 st .
Varies	FAPTP Follow-Back Deadline	All unmatched cases from FAPTP must be resolved each year

2022-2023 Monthly NAACCR Cancer Surveillance Webinar Series

FCDS is pleased to offer another year of the Monthly NAACCR Cancer Registry and Surveillance Webinar Series - Free of Charge to Florida Registrars in Recorded Sessions.

NAACCR is providing FCDS with 110 live attendance portals for 110 Florida registrars.


For registrars who do not make the short list for the live sessions, FCDS offers every NAACCR Webinar as a recorded session in FLccSC. You can still earn 3 CEUs per webinar in FLccSC. Recordings appear in FLccSC within a week or two following the live session

The 2023-2024 NAACCR Webinar Series begins on October 5, 2023 and continues through September 4, 2024. The 2023-2024 Webinar Series Schedule is provided below.

FCDS and NAACCR have an established agreement whereby any Florida FLccSC User MUST have *at least* one 'Active' User Permission or User Access Role in at least one Florida facility in IDEA to view NAACCR Webinar Recordings. All other recordings are available to any user with or without a FCDS IDEA User Role. User Roles must be updated every 6 months. FCDS recently introduced automation of access permissions that will check your individual access permission status every time you log into FLccSC regardless of how you access FLccSC (via IDEA or web). If you do not have current access to at least one facility you will not be given permission to access the NAACCR Recordings. The recordings will not even show up in your FLccSC Available Courses Menu.

DATE	TOPIC
10/5/23 9am & 2pm	Lung 2023 Part 1 Co-host: Wilson Apollo Part 1 of the Lung webinar will focus on the treatment of lung cancer. We will discuss the surgery, lymph node related data items, systemic treatment, and radiation.
11/1/23 2pm 11/2/23	Lung 2023 Part 2 Co-host: Denise Harrison Part 2 of the Lung webinar will focus on SSDIs and staging. Examples, quizzes, and case scenarios included.
12/7/23 9am & 2pm	Radiology and Radiation (R&R) Co-host: Wilson Apollo During the webinar we will focus on imaging tools used to diagnose and stage and radiation tools used for treatment. We will discuss using information from radiology and radiation reports when abstracting.
1/10/24 2pm 1/11/24	Liver and Bile Ducts 2024 Co-host: Denise Harrison This webinar will cover anatomy, solid tumor rules, staging and treatment of liver and bile duct primary malignancies. Examples, quizzes, and case scenarios included.
1/31/24 2pm 2/1/24	Pancreas 2024 Co-host: Vicki Hawhee This webinar will cover anatomy, solid tumor rules, staging and treatment of pancreatic primary malignancies. Examples, quizzes, and case scenarios included.
3/6/24 2pm 3/7/24	Boot Camp 1 2024 Co-host: Juliet Wilkins We will have 2 boot camps this year! This will allow us to spend more time on core casefinding and abstracting activities. We will spend most of our time completing and reviewing quizzes, exercises, and case scenarios. There will be minimal lecture.
4/3/24 2pm 4/4/24	Boot Camp 2 2024 Co-host: Nancy Etzold We will have 2 boot camps this year! This will allow us to spend more time on core casefinding and abstracting activities. We will spend most of our time completing and reviewing quizzes, exercises, and case scenarios. There will be minimal lecture.
5/1/24 2pm 5/2/24	Ovary 2024 Co-host: Connie Boone This webinar will cover anatomy, solid tumor rules, staging and treatment of ovarian primary malignancies. Examples, quizzes, and case scenarios included.
6/5/24 2pm 6/6/24	Thyroid 2024 Guest Presenters: Amy Bamburg and Gillian Howell This webinar will cover anatomy, solid tumor rules, staging and treatment of thyroid primary malignancies. Examples, quizzes, and case scenarios included
7/10/24 2pm 7/11/24	Life in a CoC Accredited Facility in 2024 Guest Presenters: Jennie Jones and Kim Rodriguez Join us for a discussion of life in a CoC accredited facility and how registrars help maintain accreditation. Kim and Jennie will discuss how they prepare for survey, quality control, RCRS, and much more!
7/31/24 2pm 8/1/24 9am	CNS 2024 Co-host: Carol Kruchko and Jennifer Ruhl This webinar will cover anatomy, solid tumor rules, staging and treatment for benign and malignant primaries of the central nervous system. We will also see how the Central Brain Tumor Registry of the United States is using our data to perform research. Examples, quizzes, and case scenarios included
9/4/24 2pm 9/5/24	Coding Pitfalls 2024 Co-host: Janet Vogel During this webinar we will review problematic coding issues identified through quality control of registry data.

FCDS 2023 Annual Meeting CEU Application in Progress:



Florida Cancer Data System

Cancer Reporting Completeness Report



TOTAL NUMBER OF CASES IN THE FCDS MASTER FILE AS OF AUGUST 31, 2023

Total number of *New Cases* added to the FCDS Master file in August, 2023 18,424

The figures shown below reflect initial patient encounters (admissions) for cancer by year.

ADMISSION YEAR	HOSPITAL	RADIATION	AMBI/ SURG	DERMATOLOGY	PHYSICIANS CLAIMS	DCO	TOTAL CASES	NEW CASES	Tumors
2023	3,112	67	0	5,985	0	Pending	9,164	3,584	5,963
2022	200,064	3,458	641	13,411	5,214	Pending	222,788	10,730	116,975
2021	240,150	6,969	1,056	12,584	34,305	Pending	295,064	4,110	163,357
				<u>Actual</u>	<u>Expected</u>				<u>Expected</u>
	% Complete for:	2023	4%	17%					
		2022	89%	100%	2023			5%	
		2021	100%	100%	2022			90%	
					2021			100%	

*Expected % based on 250,000 reported cases per year

Missed an FCDS or NAACCR Webinar?



Did you know that FCDS Webcasts and NAACCR Webinars can be viewed after-the -fact?

FCDS Webcasts and NAACCR Webinars are recorded and posted on the FCDS FLccSC LMS Site.

The FCDS Webcast recordings are available free of charge and can be viewed any-time/anywhere by anybody. NAACCR Webinars are restricted approved Florida FLccSC Users per FCDS/NAACCR agreement.

FCDS holds all FCDS/NAACCR recordings for 2 years before ‘retiring’ them due to outdated information.

Registrars must have an active Florida FLccSC Account and must take and pass the CEU Quiz as required to obtain some of the CEUs for certain FCDS Webcasts... always to obtain a Certificate of Attendance.

NAACCR Webinars have their own CEU award mechanism whether viewed live or via a recorded session.

Only Florida registrars with Active/Current FCDS Abstractor Codes can access the NAACCR Webinars.

Please contact FCDS for more information on viewing recorded webinars.

The Florida Cancer Data System (FCDS) is Florida's statewide, population-based cancer registry and has been collecting incidence data since 1981 when it was contracted by the State of Florida Department of Health in 1978 to design and implement the registry. The University of Miami Miller School of Medicine has been maintaining FCDS (<http://fcds.med.miami.edu>) since that time.

The FCDS is wholly supported by the State of Florida Department of Health, the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC) and the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

PROJECT DIRECTOR:

David Lee, PhD

DEPUTY PROJECT DIRECTOR:

Gary M. Levin, BA, CTR

EDITORS:

Gary M. Levin, BA, CTR
Megsys C. Herna, BA, CTR
Melissa K. Williams

EDITOR ASSISTANT/ GRAPHICS DESIGNER:

Melissa K. Williams
Danielle Simmons

CONTRIBUTORS:

Megsys C. Herna, BA, CTR
Monique Hernandez, PhD

FCDS

PO Box 016960 (D4-11)
Miami, FL 33101

Phone: 305-243-4600
800-906-3034
Fax: 305-243-4871

<http://fcds.med.miami.edu>

